Activity of Novel Antimicrobials against Gram-Negative Clinical Pathogens and Characterization of Their Resistance Mechanisms

A special issue of Antibiotics (ISSN 2079-6382).

Deadline for manuscript submissions: closed (15 May 2024) | Viewed by 654

Special Issue Editors


E-Mail Website
Guest Editor
1. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
2. Clinical Microbiology and Virology Unit, Florence Careggi University Hospital, Florence, Italy
Interests: antimicrobial resistance; AMR; Klebsiella pneumoniae; metallo-β-lactamases; β-lactamase inhibitor resistance; nosocomial outbreaks; plasmid-mediated resistance; fosfomycin resistance; molecular detection systems; antimicrobial susceptibility testing; carbapenemases; NDM; KPC

E-Mail Website
Guest Editor
Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden
Interests: antimicrobial resistance; molecular epidemiology; novel antimicrobial agents; resistance mechanisms; gram-negative bacilli

Special Issue Information

Dear Colleagues,

The increase in infections caused by bacterial pathogens resistant to most available antibiotics has a significant impact on global health. In 2016, the World Health Organization enumerated a priority list of 12 species for which the discovery of new antibiotics was urgently required, including multidrug-resistant and carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa, as well as carbapenem-resistant and/or third-generation cephalosporin-resistant Enterobacteriaceae. Therefore, in the last few years, several novel agents were approved by medicine regulatory agencies, while others are in late clinical development. The combination of new β-lactams with old β-lactamase inhibitors (BLIs), or the establishment of antibiotics with new BLIs, is the most general approach adopted, followed by the modification of the chemical structure of old antibiotics. The aim of this Special Issue is to promote the dissemination of studies evaluating the activity of novel antimicrobial agents against local and nationwide collections of Gram-negative clinical isolates. Studies characterizing resistance mechanisms responsible for the reduced activity of novel drugs will be prioritized. Surveillance studies are of paramount importance to monitor the emergence of novel antibiotic resistance and to provide useful data for the implementation of infection prevention and control and antibiotic stewardship measures.

Dr. Marco Coppi
Dr. Chaitanya Tellapragada
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cefiderocol
  • ceftolozane/tazobactam
  • ceftazidime/avibactam
  • aztreonam/avibactam
  • meropenem/vaborbactam
  • imipenem/relebactam
  • plazomicin
  • eravacycline
  • cepefime/taniborbactam
  • delafloxacin

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop